



My we claim

Claims

1. A compound of the formula




10 ~~TOZAY~~ ~~B~~ wherein A is the group  
or  $-(CH_2)_5-$




- 8  
9  
15 ~~B~~ 2. The compound of claim 1, (2S,3S,5S,7Z,10Z)-5-[(S)-2-  
formamido-4-methyl-valeryloxy]-2-hexyl-3-hydroxy-7,10-  
hexadecadienoic acid lactone.
- 20 ~~B~~ 3. The compound of claim 1, (2S,3S,5S)-5-[(S)-2-formamido-  
4-methyl-valeryloxy]-2-hexyl-3-hydroxy-hexadecanoic  
lactone.

4. A pharmaceutical composition comprising

25 a) about 5% to about 95% of a compound of  
formula



35 wherein A is the group  
or  $-(CH_2)_5-$ ; and



2200  
PS  
b) 5% to 95% of a pharmaceutically acceptable carrier material, said composition being formulated in a unit dosage form.


5. The composition of claim 4 wherein said composition is formulated in an oral unit dosage form.

6. The composition of claim 5 wherein said oral unit dosage form is a tablet, dragee, capsule, solution, emulsion or suspension.

8 9  
B 10 7. The composition of claim 4 wherein compound I is (2S, 3S, 5S, 7Z, 10Z)-5-[(S)-2-formamido-4-methyl-valeryloxy]-2-hexyl-3-hydroxy-7,10-hexadecadienoic acid lactone.

8 15  
B 16 8. The composition of claim 4 wherein compound I is (2S, 3S, 5S)-5-[(S)-2-formamido-4-methyl-valeryloxy]-2-hexyl-3-hydroxy-hexadecanoic acid lactone.

20 9. A method of treating obesity in an afflicted mammal comprising administering to the mammal a compound of the formula



30 T0261X  
PS PS wherein A is the group  
or  $W(CH_2)_5W$


PS in an amount which is effective in treating obesity.

8 9  
B 35 10. The method of claim 9 wherein compound I is (2S, 3S, 5S, 7Z, 10Z)-5-[(S)-2-formamido-4-methyl-valeryloxy]-2-hexyl-3-hydroxy-7,10-hexadecadienoic acid lactone.

8 9  
B 9 11. The method of claim 9 wherein compound I is (2S, 3S,5S)-5-[(S)-2-formamido-4-methyl-valeryloxy]-2-hexyl-3-hydroxy-hexadecanoic acid lactone.

12. The method of claim 9 wherein compound I is administered in a daily dose of about 0.1 mg to 100 mg/kg body weight of the mammal.

13. A method of treating hyperlipaemia in an afflicted mammal comprising administering to the mammal a compound of the formula




8 1  
B 14. The method of claim 13 wherein compound I is (2S, 3S,5S,7Z,10Z)-5-[(S)-2-formamido-4-methyl-valeryloxy]-2-hexyl-3-hydroxy-7,10-hexadecadienoic acid lactone.

5 1  
B 15. The method of claim 13 wherein compound I is (2S, 3S,5S)-5-[(S)-2-formamido-4-methyl-valeryloxy]-2-hexyl-3-hydroxy-hexadecanoic acid lactone.

30 16. The method of claim 13 wherein compound I is administered in a daily dose of about 0.1 mg to 100 mg/kg body weight of the mammal.

17. A method of preventing obesity in a mammal comprising administering to the mammal a compound of the formula



wherein A is the group  
 or  $-(CH_2)_5-$   
 in an amount which is effective in preventing obesity.

TO281y

PS<sub>10</sub> PS

by inhibiting Pancrease lipase

18. The method of claim 17 wherein compound I is (2S, 3S, 5S, 7Z, 10Z)-5-[(S)-2-Formamido-4-methyl-valeryloxy]-2-hexyl-3-hydroxy-7,10-hexadecadienoic acid lactone.


B

19. The method of claim 17 wherein compound I is (2S, 3S, 5S)-5-[(S)-2-formamido-4-methyl-valeryloxy]-2-hexyl-3-hydroxy-hexadecanoic acid lactone.

B

20. The method of claim 17 wherein compound I is administered in a daily dose of about 0.1 mg to 100 mg/kg body weight of the mammal.

21. A commercially-produced foodstuff comprising a compound of the formula



22. The foodstuff of claim 20 wherein compound I is (2S, 3S, 5S, 7Z, 10Z)-5-[(S)-2-formamido-4-methyl-valeryloxy]-2-hexyl-3-hydroxy-7,10-hexadecadienoic acid lactone

23. The foodstuff of claim 20 wherein compound I is (2S, 3S,5S)-5-[(S)-2-formamido-4-methyl-valeryloxy]-2-hexyl-3-hydroxy-hexadecanoic acid lactone.

5

10

15

20

25

30

35